Objective: To evaluate efficacy and safety of long duration dual anti-platelet therapy i.e., > 12 months (L-DAPT) and short duration DAPT i.e., ≤ 12 months (S-DAPT) after various drug eluting stent (DES) implantation.
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INTRODUCTION:
Dual antiplatelet therapy (DAPT) using a combination of aspirin and a P2Y12 inhibitor is used for the prevention of ischemic complications after drug-eluting stent(s) (DES)
implantation. It is estimated that more than 10 million DES have been implanted globally; however, the optimal duration of DAPT after DES implantation still remains AHA/ACC recommendations on DAPT duration were primarily on the basis of observational and pathological studies involving mainly first generation DES [2] . Second generation of DES utilizes thinner stent struts, have improved polymer biocompatibility and lower drug concentration and shown to have superior endothelialization in animal models and human autopsy studies [4, 5] . Thus, short duration DAPT (S-DAPT) might be sufficient for patients with second generation DES. In this study we performed a metaanalysis of randomized control trials (RCTs) to compare the efficacy and safety of S-DAPT (i.e., ≤ 12 months) and long duration DAPT (L-DAPT;i.e., > 12 months) in patients with first and second generation of DES. In subgroup analysis we further compare efficacy and safety of S-DAPT and L-DAPT after most commonly used second
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generation DES: zotarolimus-eluting (ZES;Endeavor®) and everolimus-eluting stents (EES;Xience V®).
METHODS:
Study Design: We followed the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) statement for reporting systematic reviews and metaanalyses of RCTs for the protocol of our meta-analysis [6] . Angiography and Interventions). DAPT was defined as aspirin plus a P2Y12 receptor inhibitor, after coronary DES implantation. S-DAPT and L-DAPT were defined as duration of DAPT after DES implantation </=12months and >12months respectively. All relevant combinations of following keywords "aspirin", "P2Y12 receptor inhibitor ", "clopidogrel", "Plavix", "prasugrel", "Effient", "ticagrelor", "Brilinta", "thienopyridine", "dual antiplatelet therapy", "DAPT", "drug eluting stents", "DES", "first generation DES", sirolimus eluting stent, SES, paclitaxel eluting stent, PES, second generation DES, zotarolimus eluting stent, ZES, everolimus eluting stent, "EES", "death", "mortality", "survival", "cardiac mortality", "stent thrombosis", "Thrombolysis In Myocardial
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Infarction (TIMI) bleeding", stroke, myocardial infarction, "randomized controlled trial", "random", "random allocation", "double-blind", and "single-blind" were included for database search. We manually searched references of identified studies. The search period took place from 1 January 2002 to 30 June 2015. No language restrictions were applied. Studies, which did not report the numbers of events with each specific DES type,
were excluded from the analysis. First-generation DES included sirolimus-eluting stent (SES) and paclitaxel-eluting stent (PES); second-generation DES included EES and ZES
DES.
Data extraction: Two reviewers (AS, AG) independently screened the titles and abstracts for relevance. The manuscripts of selected titles/abstracts were reviewed for inclusion or exclusion using the above mentioned selection criteria. Two reviewers (AS, AG)
independently determined the articles to be included and excluded, and data from the relevant articles were extracted using pre-defined extraction forms. Any disagreements in data extraction were discussed until consensus was reached. (Figure 3 ). .41] in DAPT and OPTIMIZE studies respectively [9, 11] .
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DISCUSSION
In the present analysis of RCTs in which patients were analyzed according to type of DES they received, S-DAPT as compared to L-DAPT was associated with higher rates of
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MI without any significant difference in the rate of all cause mortality, CV mortality and stroke after first and second generation DES. Rate of ST was also higher with S-DAPT compared to L-DAPT after first generation DES implantation; however, it was not significantly different after second generation DES. On further subgroup analysis of second-generation stent there was no significant difference in the rate of all cause mortality, CV mortality, MI, ST and stroke with S-DAPT and L-DAPT after ZES implantation.
Although it is estimated that more than 600,000 stents are implanted annually in United
States alone (most of them are DES), the optimum duration of DAPT remains unclear [1-4]. Several small-medium size RCTs have shown that S-DAPT led to reduction in bleeding complications without any significant increase in the rate of ischemic complications compared to L-DAPT after DES implantation [7, 8, [10] [11] [12] . However, this has been challenged in recent and largest RCT -the Dual Antiplatelet Therapy study-that has shown significant reduction in the risks of ST and major adverse CV events with L-DAPT [9] . Further, pooled analyses of various RCTs have reported conflicting results [13] [14] [15] [16] [17] [18] . One of the reasons for inconsistence in results is inclusion and combined analysis of studies that have enrolled patients with different DES. Giustino et al showed an increased risk of ST and lower risk of bleeding with S-DAPT compared to L-DAPT [13] . Navarese and colleagues have reported lower bleeding risk and no difference in ischemic complications with S-DAPT (<12months) compared with a standard 12-month duration DAPT [14] . Further, they have reported an increase in all cause mortality with L-DAPT (>12months) [14] . To our knowledge this is the first meta-analysis, which
evaluated the outcomes with S-and L-DAPT duration in various stent types. In this study we have included data from RCTs only and have reported each end point separately instead of using composite endpoints like major adverse CV event) or major adverse CV and cerebrovascular event or net clinical benefit. Thus, avoiding the serious limitation associated with composite end points, as it is based on the assumption that each component of this pooled endpoint will have a similar impact on health, will change in the same "direction" with regards to the active treatment, and will be of equal importance to patients and their providers, which in turn is not true [19] . Different effects of the trial intervention might be observed on the individual trial endpoints, which would be subsequently blurred when aggregated into a single composite outcome.
Although different DES varies in stent design and drug release kinetics, fundamentally they all release pharmacologic agents that suppress neo-intimal hyperplasia, thus reducing the rate of in-stent restenosis as compared to bare metal stent (BMS). However, these pharmacological agents locally released from DES also impair arterial healing which leads to delay and sometimes-incomplete endothelization in the stented portion of the vessel and thus increasing the risk of late ST when compared to BMS [20] . DAPT can reduce the risk of ST [20] . Thus, theoretically compared to BMS all DES required -DAPT to reduce the risk of ST. However, the optimum duration of DAPT required after DES implantation remains debatable.
The first DES approved for clinical use in US was the SES, which was coated with a natural macrocyclic lactone-sirolimus-which have an antiproliferative and
immunosuppressive effects. Sirolimus block smooth muscle cell cycle transition from G1
to S phase by inhibiting mammalian target of rapamycin (mTOR) [21] . Another first generation DES approved by Federal Drug Administration within a year of SES approval was PES, which uses another naturally occurring antiproliferative agent-Paclitaxel, which block cell cycle in G0/G1 and G2/M phases by stabilizing the microtubules.
Although first generation DES were shown to have better clinical outcomes compared to BMS, there was an increased risk of late ST with use of first generation DES, especially after discontinuation of DAPT [22, 23] . Pathological studies have shown that delayed arterial healing due to slow endothelization was present in all cases of late ST in patients with DES [24] . Second generation DESs were designed to overcome many of these limitations. Second generation DESs have thin stent struts (80-90μm), which led to more rapid re-endothelization by reducing the neointimal response [25] . In addition to decreased strut thickness, second generation of DES have optimized polymer biocompatibility and drug delivery kinetics and shown to have superior endothelialization in animal models and human autopsy studies [25, 26, 27] . In a large singe center registry, Dores and colleagues have reported significant reduction in rate of definite stent thrombosis with use of second generation DES compared to first generation DES [28] .
Thus, S-DAPT might be sufficient for patients with second generation DES, while L-DAPT can be considered after first generation DES implantation, especially is bleeding risk is low [29, 30, 31] .
However, there are a number of limitations to the current analysis. First, this is a metaanalysis performed on study-level data due to non-availability of patient level data. Thus, landmark analysis could not be performed to address this issue in our study.
Conclusion: 1) Compared with L-DAPT, S-DAPT was associated with higher rate of MI without any significant difference in the rate of all cause mortality, CV mortality and stroke after first and second generation DES.
2) Rate of ST was also higher with S-DAPT compared to L-DAPT after first generation DES implantation; however, it was not significantly different after second generation DES. 3) On further subgroup analysis of second-generation stent there was no significant difference in the rate of all cause mortality, CV mortality, MI,ST and stroke with S-DAPT and L-DAPT after ZES implantation. Shorter duration DAPT may be optimum for newer generation stents particularly ZES.
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